Hormone therapy for radiorecurrent prostate cancer

World Journal of Urology

Volumn 31, Issue 6, 2013, Pages 1333-1338

  Payne, H ^a   Khan, A ^a   Chowdhury, S ^a   Davda, R ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Hormone therapy; Prostate cancer; Radiorecurrence

Indexed keywords

ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; NITRILE; PROSTATE SPECIFIC ANTIGEN; TOLUENESULFONIC ACID DERIVATIVE;

ARTICLE; BLOOD; GYNECOMASTIA; HUMAN; MALE; MASTALGIA; PROSTATE TUMOR; RADIOTHERAPY; RECURRENT DISEASE; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; GYNECOMASTIA; HUMANS; MALE; MASTODYNIA; NEOPLASM RECURRENCE, LOCAL; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY; RECURRENCE; RISK FACTORS; TOSYL COMPOUNDS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84888297632     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-012-0952-8     Document Type: Article

References (23)

1. Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4): 965-974.
2. D'Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974.
3. Zietman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF, Zlotecki RA et al (1996) Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 40: 159-162.
4. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA et al (2005) PSAnadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Int J Radiat Oncol Biol Phys 64(4): 1140-1150.
5. Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A et al (2005) Failure definition dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys 61: 409-414.
6. Rybalov M, Breeuwsma AJ, Leliveld AM, Pruim J, Dierckx RA, de Jong IJ (2012) Impact of total PSA, PSA doubling time and PSA velocity on detection rates of (11)C-Choline positron emission tomography in recurrent prostate cancer. World J Urol (Epub ahead of print).
7. Rybalov M, Breeuwsma AJ, Pruim J, Leliveld AM, Rosati S, Veltman NC, Dierckx RA, De Jong IJ (2012) [11C]choline PET for the intraprostatic tumor characterization and localization in recurrent prostate cancer after EBRT. Q J Nucl Med Mol Imaging 56(2): 202-208 (Epub 2012 Mar 9).
8. Dudderidge T, Payne H, Emberton M (2007) An algorithm for managing the failure of external beam radiotherapy in prostate cancer. BJU Int 100(3): 518-527.
9. Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A (2005) Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol 173: 1456-1462.
10. Kwan W, Pickles T, Duncan G, Liu M, Agranovich A, Berthelet E, Keyes M, Kim-Sing C, Morris WJ, Paltiel C (2004) PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 60(4): 1040-1046.
11. Lee AK, Levy LB, Cheung R, Kuban D (2005) Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63: 456-462.
12. Faria SL, Mahmud S, Souhami L, David M, Duclos M, Shenouda G et al (2006) No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. Urology 67: 142-146.
13. Pinover WH, Horwitz EM, Hanlon AL, Uzzo RG, Hanks GE (2003) Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy. Cancer 97(4): 1127-1133.
14. Parker CC, Dearnaley DP (1998) The management of PSA failure after radical radiotherapy for localized prostate cancer. Radiother Oncol 49: 103-110.
15. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth M, On behalf of the Casodex Early Prostate Cancer Trialists' Group (2005) Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97: 247-254.
16. Iversen P et al (2002) A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early nonmetastatic prostate cancer. Eur Urol 42: 204-211.
17. Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. NEJM 352: 2.
18. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S (2004) Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 171 (6 Pt 1): 2272-6, quiz 2435.
19. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM, Robertson C (2009) Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group C. Eur Urol 55(6): 1269-1277.
20. de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L et al (2002) Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 1(3): 163-171.
21. Maha Hussain, Catherine M. Tangen, Celestia S. Higano, E. David Crawford et al. (2012) Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trialJ Clin Oncol 30 (suppl; abstr 4).
22. Moinpour C, Berry DL, Ely B, Tangen CM, Higano CS et al (2012) Preliminary quality-of-life outcomes for SWOG-9346: Intermittent androgen deprivation in patients with hormone-sensitive metastatic prostate cancer (HSM1PC)-Phase III. J Clin Oncol 30 (suppl; abstr 4571).
23. Klotz L, Occ J, Ding K et al (2011) A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR. 7/SWOG JPR. 7/CTSU JPR. 7/UK Intercontinental Trial CRUKE/01/013. J Clin Oncol 29 (suppl 7, abstract 3).